Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Co-Diagnostics Inc is a medical devices business based in the US. Co-Diagnostics shares (CODX) are listed on the NASDAQ and all prices are listed in US Dollars. Co-Diagnostics employs 101 staff and has a trailing 12-month revenue of around $78.2 million.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $2.96 |
|---|---|
| 52-week range | $2.76 - $10.90 |
| 50-day moving average | $4.58 |
| 200-day moving average | $5.88 |
| Wall St. target price | $13.00 |
| PE ratio | 3.2128 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.94 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.96 from 2022-09-27
| 1 week (2022-09-21) | 1.37% |
|---|---|
| 1 month (2022-08-26) | -16.62% |
| 3 months (2022-06-28) | -41.85% |
| 6 months (2022-03-28) | -51.87% |
| 1 year (2021-09-28) | -69.89% |
|---|---|
| 2 years (2020-09-28) | -79.15% |
| 3 years (2019-09-27) | 176.64% |
| 5 years (2017-09-28) | 6.12 |
Valuing Co-Diagnostics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Co-Diagnostics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Co-Diagnostics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 3x. In other words, Co-Diagnostics shares trade at around 3x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Co-Diagnostics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.5 million.
The EBITDA is a measure of a Co-Diagnostics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $78.2 million |
|---|---|
| Operating margin TTM | 37.86% |
| Gross profit TTM | $86.3 million |
| Return on assets TTM | 14.6% |
| Return on equity TTM | 24.17% |
| Profit margin | 35.8% |
| Book value | $4.28 |
| Market capitalisation | $102 million |
TTM: trailing 12 months
We're not expecting Co-Diagnostics to pay a dividend over the next 12 months.
Over the last 12 months, Co-Diagnostics's shares have ranged in value from as little as $2.76 up to $10.9. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Co-Diagnostics's is -0.7691. This would suggest that Co-Diagnostics's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Co-Diagnostics has bucked the trend.
Co-Diagnostics, Inc. , a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah. .
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.
